Revalesio to present research on the anti-inflammatory effects of RNS60 in Asthma
Date: March 16, 2011
Tacoma, WA – Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San Francisco on March 18-22.
AAAAI is the largest professional organization in the United States devoted to the specialty of allergy and immunology. It has nearly 6,500 members in the United States, Canada and 60 other countries.
Revalesio will present findings that demonstrate the novel anti-inflammatory activity of charge-stabilized nanostructures both in a preclinical model of allergic asthma and in cell culture experiments. These data suggest that Revalesio’s novel therapeutic RNS60 provides an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases.
In the preclinical model of asthma, RNS60 showed significant efficacy in the reduction of key inflammatory cytokines, including interleukin-6, interleukin-4, tumor necrosis factor-α (TNF-α), eotaxin and other cytokines known to be drivers of asthma. In addition to reducing inflammatory cytokines, RNS60 improved respiratory parameters compared to treatment with the inhaled corticosteroid budesonide.
The presented cell culture studies demonstrate the anti-inflammatory activity of RNS60 by decreasing the production of key inflammatory mediators of asthma, including C-C chemokine receptor type 3 (CCR3) and interleukin-8. The research also demonstrates that RNS60 exerts its effects through the modulation of whole cell conductance.
RNS60 is currently in a Phase I/IIa clinical trial at Stanford University for allergic asthma.
About charge-stabilized nanostructures (CSN)
Revalesio has pioneered the novel use of charge-stabilized nanostructures to alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the expression of G protein-coupled receptors and the secretion of cytokines, chemokines and adhesion molecules. These changes to whole cell conductance reduce inflammatory signals that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.
About Revalesio Corporation:
Revalesio is a pioneering biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is pioneering the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.